Premium
Potential Site to Direct Selective Compounds in the Triosephosphate Isomerase for the Development of New Drugs
Author(s) -
BenítezCardoza Claudia G.,
JiménezPineda Albertana,
AnglesFalconi Sergio I.,
FernándezVelasco Daniel A.,
ViqueSánchez José L.
Publication year - 2020
Publication title -
chemistryselect
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.437
H-Index - 34
ISSN - 2365-6549
DOI - 10.1002/slct.202000820
Subject(s) - triosephosphate isomerase , drug development , enzyme , isomerase , chemistry , computational biology , biochemistry , drug , pharmacology , biology
Abstract In the pharmaceutical industry, the development of selective drugs to an enzyme or the repositioning of commercial drugs, today, is booming. The glycolytic enzyme triosephosphate isomerase (TIM) has been used as a therapeutic target for the development of new drugs against various pathogenic organisms. Therefore, saving resources in the development of new drugs, by directing the interaction of pharmacological compounds to an interaction site with a high probability to be selective, represents an opportunity for researchers.